What is drug safety? Celebrating 20 years of the Drug Safety journal

Drug Safety

Volumn 29, Issue 6, 2006, Pages 461-465

  Edwards, I Ralph ^a  

^a WHO Foundation Collaborating Centre for International Drug Monitoring   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BENOXAPROFEN; NONSTEROID ANTIINFLAMMATORY AGENT;

BLEEDING; DRUG MONITORING; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; EDITORIAL; FRANCE; GASTROINTESTINAL HEMORRHAGE; HUMAN; LIVER TOXICITY; PHARMACOEPIDEMIOLOGY; PRIORITY JOURNAL; PUBLIC HEALTH; WORLD HEALTH ORGANIZATION;

ADVERSE DRUG REACTION REPORTING SYSTEMS; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; INTERNATIONAL COOPERATION; PERIODICALS; PHARMACEUTICAL PREPARATIONS; PHARMACOEPIDEMIOLOGY;

EID: 33744955629     PISSN: 01145916     EISSN: 01145916     Source Type: Journal    
DOI: 10.2165/00002018-200629060-00001     Document Type: Editorial

References (28)

1. Borda I, Jick H, Slone D, et al. Studies of drug usage in five Boston hospitals. JAMA 1967 Nov 6; 202 (6): 506-10
2. Rossi AC, Hsu JP, Faich GA. Ulcerogenicity of piroxicam: an analysis of spontaneously reported data. Br Med J (Clin Res Ed) 1987 Jan 17; 294 (6565): 147-50
3. Pond SM, Prescott LF, Goldfrank L. Why medical toxicology. Med Toxicol 1986; 1 (1): 1-2
4. Carson JL, Strom BL. Techniques in postmarketing surveillance: an overview. Med Toxicol 1986; 1 (4): 237-46
5. Glen-Bott M. Aspirin and Reye's syndrome: a reappraisal. Med Toxicol Adverse Drug Exp 1987; 2 (3): 161-5
6. McEwen J. Improving adverse drug reaction monitoring. Med Toxicol Adverse Drug Exp 1987; 2 (6): 398-404
7. Edwards IR. Adverse drug reaction monitoring: the practicalities. Med Toxicol Adverse Drug Exp 1987; 2 (6): 405-10
8. Dukes MNG. The importance of adverse reactions in drug regulation. Drug Saf 1990; 5 (1): 3-6
9. Bem JL, Wood SM, West L, et al. 25 Years of the Committee of Safety of Medicines: an international perspective of the benefits. Drug Saf 1990; 5 (3): 161-7
10. Hollenberg NK, Testa M, Williams GH. Quality of life as a therapeutic end-point: an analysis of therapeutic trials in hypertension. Drug Saf 1991; 6 (2): 83-93
11. Naranjo CA, Lanctot KL. Recent developments in computer-assisted diagnosis of putative adverse drug reactions. Drug Saf 1991; 6 (5): 315-22
12. Suissa S. Statistical methods in pharmacoepidemiology: principles in managing error. Drug Saf 1991; 6 (5): 381-9
13. Stephens MDB. Marketing aspects of company-sponsored postmarketing surveillance studies. Drug Saf 1993; 8 (1): 1-8
14. Wallander M-A. The way towards adverse event monitoring in clinical trials. Drug Saf 1993; 8 (5): 251-62
15. Edwards IR, Biriell C. Harmonisation in pharmacovigilance. Drug Saf 1994; 10 (2): 93-102
16. Pirmohamed M, Kitteringham NR, Park BK. The role of active metabolites in drug toxicity. Drug Saf 1994; 11 (2): 114-44
17. Edwards IR, Wiholm B-E, Martinez C. Concepts in risk-benefit assessment: a simple merit analysis of a medicine? Drug Saf 1996; 15 (1): 1-7
18. Hauben M, Zhou X. Quantitative methods in pharmacovigilance: focus on signal detection. Drug Saf 2003; 26 (3): 159-86
19. Almenoff J, Tonning JM, Gould AL, et al. Perspectives on the use of data mining in pharmacovigilance. Drug Saf 2005; 28 (11): 981-1007
20. Brown EG. Methods and pitfalls in searching drug safety databases utilising the medical dictionary for regulatory activities (MedDRA). Drug Saf 2003; 26 (3): 145-58
21. Berry DC, Raynor DK, Knapp PR, et al. Patient understanding of risk: impact of EU guidelines and other risk scales for consumer medicines information. Drug Saf 2003; 26: 1-11
22. van Grootheest K, de Graaf L, de Jong-van den Berg LTW. Consumer adverse drug reaction reporting: a new step in pharmacovigilance? Drug Saf 2003; 26 (4): 211-7
23. Chua S-S, Wong ICK, Edmondson H, et al. A feasibility study for recording of dispensing errors and 'near misses' in four UK primary care pharmacies. Drug Saf 2003; 26 (11): 803-13
24. Hoffman J, Proulx S. Medication errors caused by confusion of drug names. Drug Saf 2003; 26 (7): 445-52.
25. McCarter TG, Centafont R, Daly F, et al. Reducing medication errors: a regional approach for hospitals. Drug Saf 2003; 26 (13): 937-50
26. Barnes J. Pharmacovigilance of herbal medicines: a UK perspective. Drug Saf 2003; 26 (12): 829-51
27. ten Ham M. Health risks of counterfeit pharmaceuticals. Drug Saf 2003; 26 (14): 991-7
28. Segal ES, Valette C, Oster L, et al. Management strategies in the postmarketing period: safety experience with the US and European Bosentan surveillance programmes. Drug Saf 2005; 28 (11): 971-80